GENFIT S A/ADR (NASDAQ:GNFT) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Monday, Zacks.com reports. The firm currently has a $17.00 target price on the stock. Zacks Investment Research‘s target price would suggest a potential upside of 6.05% from the company’s current price.
According to Zacks, “Genfit SA is a biopharmaceutical company. It focuses on the discovery and development of therapeutic and diagnostic solutions in metabolic and liver related diseases. The company’s lead products include Elafibranor, Nitazoxanide and TGFTX1 which are in clinical stage. Genfit SA is based in Loos, France. “
GNFT has been the topic of several other reports. HC Wainwright decreased their price objective on shares of GENFIT S A/ADR from $72.00 to $58.00 and set a “buy” rating on the stock in a report on Thursday, October 31st. ValuEngine cut shares of GENFIT S A/ADR from a “buy” rating to a “hold” rating in a research note on Friday, September 27th. Finally, B. Riley restated a “buy” rating and set a $43.00 price target on shares of GENFIT S A/ADR in a research report on Tuesday, November 26th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. GENFIT S A/ADR has an average rating of “Buy” and an average target price of $42.75.
A number of hedge funds and other institutional investors have recently bought and sold shares of GNFT. Morgan Stanley boosted its stake in GENFIT S A/ADR by 24.4% during the 2nd quarter. Morgan Stanley now owns 10,700 shares of the company’s stock worth $211,000 after purchasing an additional 2,100 shares during the last quarter. Granahan Investment Management Inc. MA raised its position in shares of GENFIT S A/ADR by 4.4% in the third quarter. Granahan Investment Management Inc. MA now owns 199,695 shares of the company’s stock valued at $3,477,000 after buying an additional 8,495 shares during the last quarter. Balyasny Asset Management LLC purchased a new position in shares of GENFIT S A/ADR in the second quarter worth about $699,000. Millennium Management LLC lifted its stake in shares of GENFIT S A/ADR by 51.4% in the third quarter. Millennium Management LLC now owns 128,001 shares of the company’s stock worth $2,228,000 after buying an additional 43,464 shares in the last quarter. Finally, Bank of America Corp DE acquired a new position in GENFIT S A/ADR during the second quarter worth about $889,000. 6.46% of the stock is owned by hedge funds and other institutional investors.
About GENFIT S A/ADR
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis.
Read More: Trading on Margin
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GENFIT S A/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENFIT S A/ADR and related companies with MarketBeat.com's FREE daily email newsletter.